drugset
Drugs / Bifidobacterium quadruple live bacteria tablets
last change Dec 2021 re-read 2 minutes ago

Bifidobacterium quadruple live bacteria tablets

also known as Bifidobacterium tetrad live bacteria tablet · Si Lian Kang
Developed for
active peptic ulcer disease
Investigated by
Hangzhou Grand Biologic Pharmaceutical, Inc. · Nanjing First Hospital, Nanjing Medical University · Renmin Hospital of Wuhan University · The First Affiliated Hospital of Nanchang University · The First Affiliated Hospital of Shanxi Medical University · The First Affiliated Hospital of Zhengzhou University
+3 more · The First People's Hospital of Yunnan · Xi'an Central Hospital · Zhejiang Provincial Hospital of TCM

Trials 1 · a red edge is where a trial was stopped

today NCT04034641 · Ph 4
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT04034641 Jun 2019 → Dec 2020 active peptic ulcer disease Hangzhou Grand Biologic Pharmaceutical, Inc. Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Bifidobacterium quadruple live bacteria tablets “Bifidobacterium quadruple live bacteria tablets (Si Lian Kang)” NCT04034641 ↗
Known as Bifidobacterium tetrad live bacteria tablet ClinicalTrials.gov intervention name — accepted as the source's own label NCT04034641 ↗
Known as Si Lian Kang “Bifidobacterium quadruple live bacteria tablets (Si Lian Kang)” NCT04034641 ↗